December 04, 2014

PLEASANTON, Calif., December 1st, 2014 — CooperVision, Inc. announced expanded powers for its Biofinity® multifocal lenses, now ranging from +6.00 to -10.00. The addition of the new powers extends the comfort and visual acuity benefits of the popular silicone hydrogel monthly replacement lenses to even more presbyopes. 


In addition to existing sphere powers, Biofinity® multifocal lenses will now be available in -8.50, -9.00, -9.50, and -10.00 in +1.00, +1.50, +2.00, and +2.50 ADD powers in both D and N lens designs. The new powers will be available in dispensing 6-packs and single trial lenses starting December 1st in the United States and Canada. 


CooperVision Biofinity® multifocal is a premium lens that offers eye care practitioners a simplified approach to fitting their presbyopic patients. The lens combines key elements from the Biofinity® silicone hydrogel lens material with CooperVision’s Balanced Progressive Technology®. This advanced design contains multiple zones of vision correction in both lenses, allowing for clear vision up close, intermediate, and far away. Biofinity are the only monthly lenses with Aquaform® Technology, combining an unmatched balance of high oxygen permeability (Dk128), excellent water content (H2O 48%), and optimum modulus for a softer, more flexible lens (modulus 0.75 mPA).


# # #


About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses and related products and services. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit


About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market-leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, Calif., Cooper has approximately 8,000 employees with products sold in over 100 countries. For more information, please visit



Media Contact
Heather Kowalczyk, McDougall Communications for CooperVision, Inc. or +1-585-330-4878